cyclosporin
csa
potent
revers
immunosuppress
agent
abl
suppress
allograft
reject
acut
allogen
graftversushost
diseas
gvhd
although
csa
dramat
improv
surviv
allogen
marrow
transplant
rat
treat
short
cours
csa
develop
delay
onset
gvhd
csa
withdraw
paper
present
new
evid
indic
gvhd
may
develop
upon
csa
withdraw
follow
allogen
also
syngen
even
autolog
bone
marrow
reconstitut
rat
lewi
femal
rat
wk
old
purchas
harlan
spragu
dawley
inc
indianapoli
radiat
lewi
rat
irradi
day
rad
radmin
dual
sourc
cs
small
anim
irradi
atom
energi
canada
ltd
ottawa
ontario
legshield
rat
anesthet
chloral
hydrat
right
tibia
shield
lead
doughnut
cm
thick
cm
long
irradi
rad
marrow
transplant
donor
marrow
tibia
femur
humeri
pend
nucleat
cellsml
hank
solut
supplement
uml
penicillin
ngml
streptomycin
day
rat
receiv
ml
via
tail
vein
antibiot
rat
receiv
medic
drink
water
supplement
bactrim
neomycin
polymyxin
b
given
mgkg
gentamycin
per
day
subcutan
rat
develop
overt
clinic
infect
routin
sacrif
exclud
studi
cyclosporin
csa
gener
gift
sandoz
inc
hanov
nj
emulphor
obtain
gaf
corp
new
york
powder
csa
dissolv
absolut
ethanol
ad
emulphor
mix
water
yield
final
emulphor
concentr
rat
weigh
daili
receiv
g
bodi
weight
per
day
subcutan
day
indic
assess
gvhd
rat
examin
daili
sign
clinic
gvhd
red
ear
dermat
diarrhea
skin
biopsi
taken
frequent
interv
rat
develop
sever
clinic
gvhd
character
weight
loss
hunch
appear
extens
dermat
sacrif
autopsi
previous
describ
criteria
use
histolog
document
gvhd
grade
ii
acut
gvhd
defin
presenc
lymphocyt
exocytosi
epiderm
destruct
vacuolar
chang
basal
layer
dyskeratot
cell
adopt
transfer
gvhd
donor
spleen
suspend
hank
solut
gentli
press
spleen
stainless
steel
screen
gvhd
adopt
transfer
marrow
cell
spleen
cell
given
intraven
irradi
syngen
rat
experi
marrow
spleen
cell
pool
donor
gvhd
syngen
gvhd
lethal
irradi
lewi
rat
reconstitut
syngen
bone
marrow
treat
control
diluent
csa
syngen
radiat
chimera
treat
csa
rule
develop
clinic
histolog
gvhd
seven
independ
syngen
transplant
chimera
treat
csa
develop
gvhd
autopsi
rat
intens
sialodacroaden
suggest
underli
coronaviru
infect
contrast
rat
reconstitut
syngen
marrow
treat
csa
mgkg
per
day
develop
clinic
histolog
gvhd
p
tabl
gvhd
seen
rat
receiv
csa
erythemat
ear
dermat
hair
loss
diarrhea
weight
loss
observ
rat
csa
stop
characterist
histolog
lesion
gvhd
seen
skin
tongu
esophagu
liver
fig
pronounc
lymphoid
atrophi
thymu
spleen
lymph
node
observ
syngen
chimera
develop
gvhd
cours
csa
lymphoid
atrophi
less
strike
rat
develop
gvhd
posttranspl
csa
treatment
larg
number
lymphoblast
observ
lymph
node
rat
day
autolog
gvhd
might
argu
csa
mere
amplifi
gvhd
respons
due
subtl
genet
differ
syngen
rat
test
hypothesi
lewi
rat
irradi
rad
shield
right
tibia
lead
doughnut
four
four
legshield
csatreat
rat
develop
clinic
histolog
acut
gvhd
observ
gvhd
seven
untreat
legshield
rat
tabl
ii
adopt
transfer
syngen
autolog
gvhd
tabl
iii
show
result
four
independ
adopt
transfer
experi
syngen
gvhd
may
adopt
transfer
spleen
cell
marrow
lethal
irradi
syngen
recipi
unirradi
rat
resist
adopt
transfer
syngen
gvhd
preliminari
result
suggest
syngen
autolog
gvhd
mediat
cell
adopt
transfer
syngen
autolog
gvhd
prevent
treat
spleen
cell
potent
rabbit
antirat
thymocyt
serum
guinea
pig
complement
complement
alon
interfer
adopt
transfer
gvhd
normal
rat
refractori
adopt
transfer
syngen
gvhd
normal
untranspl
rat
develop
gvhd
csa
withdraw
data
shown
result
suggest
normal
rat
possess
activ
tolerancemaintain
mechan
prevent
develop
autolog
gvhd
transfer
establish
syngen
gvhd
tabl
iv
show
result
adopt
transfer
experi
lethal
irradi
lewi
rat
transplant
lewi
marrow
syngen
spleen
cell
rat
gvhd
one
group
lewi
rat
irradi
rad
shield
right
tibia
csatreat
rat
receiv
mgkgd
p
lethal
irradi
lewi
rat
transplant
x
lewi
marrow
cell
lewi
spleen
cell
rat
syngen
gvhd
normal
lewi
spleen
cell
also
given
rat
indic
lewi
rat
lethal
irradi
treat
csa
control
diluent
day
day
rat
transplant
x
syngen
lewi
marrow
cell
spleen
cell
indic
also
receiv
equal
number
normal
spleen
cell
rat
develop
grade
ii
acut
gvhd
shown
tabl
v
normal
spleen
cell
also
prevent
develop
syngen
gvhd
given
time
marrow
transplant
csatreat
syngen
chimera
key
observ
present
paper
consist
develop
gvhd
csatreat
rat
syngen
autolog
bone
marrow
reconstitut
develop
upon
discontinu
csa
syngen
gvhd
may
adopt
transfer
irradi
normal
syngen
recipi
syndrom
similar
syngen
autolog
gvhd
previous
describ
neonat
thymectom
mice
neonat
mice
given
larg
dose
staphylococc
vaccin
addit
isol
case
gvhd
patient
receiv
bone
marrow
ident
twin
report
exist
syngen
autolog
gvhd
provid
compel
evid
histocompat
differ
absolut
necessari
develop
gvhd
csa
low
concentr
vitro
revers
inhibit
prolif
respons
primari
mix
lymphocyt
reaction
prevent
develop
cytotox
cell
csa
appear
interfer
product
acquisit
respons
cell
growth
factor
vivo
csa
induc
state
profound
immunosuppress
abl
revers
suppress
allograft
reject
acut
allogen
gvhd
mechan
csa
caus
syngen
gvhd
present
enigmat
mechan
normal
rat
resist
adopt
transfer
establish
gvhd
remain
identifi
lethal
irradi
rat
treat
cyclosporin
csa
develop
classic
graftversushost
diseas
gvhd
reconstitut
syngen
autolog
bone
marrow
upon
discontinu
csa
wherea
normal
rat
syngen
gvhd
may
transfer
irradi
normal
syngen
recipi
normal
spleen
cell
fail
prevent
develop
adopt
transfer
syngen
gvhd
receiv
public
novemb
revis
form
march
